Fig 2: IL-8 and STC1 are critical for oncogenic roles of the educated BM-MSCs. A GSEA plots of indicated signature genes enriched in BM-MSCs incubated with si-CD44-sEV. B The Heatmap of the selected down-regulated genes related to secreted factors in si-CD44-sEV group compared with NC-sEV group. C–H qPCR of IL-8 and STC1 in BM-MSCs under indicated treatment. I-L Migration and invasion assays. M Tubule formation assay. N, O GC cells were treated with CM collected from BM-MSCs incubation with AGS-sEV and HGC-27L-sEV; Western blot analysis of CD44 levels in GC cells and their sEV. P CM from BM-MSCs educated by HGC-27L-sEV was incubated with IL-8 neutralizing antibody and STC1 antibody, respectively, and then were used to treat HGC-27. Western blotting analysis of CD44 and CPT1A in HGC-27. ***P < 0.001; ****P < 0.0001

Fig 3: Schematic diagram of LNM-GC cell sEV-CD44 induces FAO metabolic reprogramming of BM-MSCs via ERK-PPAR?-CPT1A signaling to stimulate the release of IL-8 and STC1 and promote GC lymphatic metastasis

Fig 4: m6A affects the abundance of host transcripts upregulated during KSHV reactivation. (A) RT-qPCR analysis of cellular m6A-modified transcripts in TREX-BCBL1-Rta cells induced for 24 h compared to latent levels. (B) Representative Western blot of ZFP36L1 and GPRC5A protein levels in latent and reactivated TREX-BCBL1-Rta cells. (C) RT-qPCR analysis of WTAP RNA levels in latent and lytic WTAP shRNA-treated TREX-BCBL1-Rta cells. (D) Representative Western blot of WTAP protein levels in Scr- and WTAP-shRNA-treated latent TREX-BCBL1-Rta cells. (E) RNA levels of GPRC5A, STC1, FOSB and ZFP36L1 in Scr- or WTAP shRNA-treated latent and induced TREX-BCBL-1 cells. (F) RT-qPCR analysis of FTO RNA levels in latent and lytic FTO shRNA-treated TREX-BCBL1-Rta cells. (G) Representative Western blot of FTO protein levels in Scr- and FTO-shRNA-treated latent TREX-BCBL1-Rta cells. (H) RNA levels of GPRC5A, STC1, FOSB and ZFP36L1 in Scr- or FTO shRNA-treated latent and induced TREX-BCBL1-Rta cells. (I) RT-qPCR analysis of YTHDF1 RNA levels in latent and lytic YTHDF1 shRNA-treated TREX-BCBL1-Rta cells. (J) Representative Western blot of YTHDF1 protein levels in Scr- and YTHDF1-shRNA-treated latent TREX-BCBL1-Rta cells. (K) RNA levels of GPRC5A, STC1, FOSB and ZFP36L1 in Scr- or YTHDF1 shRNA-treated latent and induced TREx-BCBL1-Rta cells. In (A,C,E,F,H,I,K), data are presented as mean ± SD. * p < 0.05, ** p < 0.01, *** p < 0.001. All repeats are biological (n = 3).